Thomas Gabrielczyk

1 week ago | european-biotechnology.com | Thomas Gabrielczyk

With its New Product Award, the SLAS, which is expanding in Europe, honours products with transformational potential in life sciences automation and preclinical drug development. On May 21, up to three winners of the New Product Award will be selected from these five finalists in Hamburg: BlueCatBio GmbH with the product Blue®CatX, DISPENDIX GmbH with the product I.

1 week ago | european-biotechnology.com | Thomas Gabrielczyk

Phabioc GmbH, a spin-off from the Karlsruhe Institute of Technology, has developed two fully automatable products that significantly improve preclinical research and drug development.

1 week ago | european-biotechnology.com | Thomas Gabrielczyk

Cambridge-based Alchemab Therapeutics Ltd has entered into a licensing agreement with Eli Lilly and Company  for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Alchemab’s platform uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from resilient individuals.

1 week ago | european-biotechnology.com | Thomas Gabrielczyk

MyxoTech GmbH offers an unprecedented pool of novel small molecules sourced from a unique phylum of bacteria called myxobacteria. Around 80% of known myxobacterial metabolite scaffolds are produced exclusively by myxobacteria. One of these scaffolds (Corallopyronin A) is nearing Phase 1 clinical trials, three metabolite scaffolds have reached clinical trials, and one of these three has been turned into FDA-approved breast cancer drug ixabepilone. This does not come as a surprise though.

1 week ago | european-biotechnology.com | Thomas Gabrielczyk

Paris-based Astraveus SAS  has partnered  with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) to evaluate a novel approach dubbed Lakhesys Benchtop Cell FactoryTM for the manufacturing of CAR-T therapies. Though providing high response rates, CAR-T cell therapies have several problems such as autologous production at hospital sites driving cost of therapies or regulary induction of cytokine release syndrome (CRS).